Development of Pediatric Dosing for Mepolizumab in Severe Asthma Based on Extrapolation of Data From Adult Patients and a Phase II Open‐Label Pediatric Trial.

The benefit–risk profile of mepolizumab in severe asthma was established through clinical trials in adults, leading to EU and US approvals in 2015. To support a pediatric indication (≥6 years), an extrapolation approach was implemented. This extrapolation and its validation were informed by data fro...

Full description

Bibliographic Details

Published in:	Journal of Clinical Pharmacology Vol. 66; no. 2; pp. 1 - 11
Main Authors:	Gupta, Atul, Pouliquen, Isabelle J., Phipatanakul, Wanda, Austin, Daren, Whelan, Glenn, Price, Robert G., Finney‐Hayward, Tricia, Derey, Sabine, Steinfeld, Jonathan
Format:	research tables/charts Journal Article
Published:	Wiley-Blackwell Feb2026
Online Access:	View this record in EBSCOhost